Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $45.09 billion. The enterprise value is $76.78 billion.
Important Dates
The next confirmed earnings date is Wednesday, July 30, 2025, before market open.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.57 billion shares outstanding. The number of shares has increased by 1.58% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.57B |
| Shares Change (YoY) | +1.58% |
| Shares Change (QoQ) | -0.21% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.56B |
Valuation Ratios
The trailing PE ratio is 62.56.
| PE Ratio | 62.56 |
| Forward PE | n/a |
| PS Ratio | 1.47 |
| Forward PS | 0.02 |
| PB Ratio | 0.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.82 |
| P/OCF Ratio | 6.39 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.32, with an EV/FCF ratio of 13.32.
| EV / Earnings | 106.53 |
| EV / Sales | 2.51 |
| EV / EBITDA | 9.32 |
| EV / EBIT | 20.42 |
| EV / FCF | 13.32 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.01 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 3.96 |
| Debt / FCF | 5.90 |
| Interest Coverage | 4.31 |
Financial Efficiency
Return on equity (ROE) is 1.52% and return on invested capital (ROIC) is 2.84%.
| Return on Equity (ROE) | 1.52% |
| Return on Assets (ROA) | 2.40% |
| Return on Invested Capital (ROIC) | 2.84% |
| Return on Capital Employed (ROCE) | 4.79% |
| Revenue Per Employee | $644,718 |
| Profits Per Employee | $15,188 |
| Employee Count | 47,455 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.29 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $447.02 million in taxes.
| Income Tax | 447.02M |
| Effective Tax Rate | 38.23% |
Stock Price Statistics
The stock price has increased by +3.92% in the last 52 weeks. The beta is 0.26, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +3.92% |
| 50-Day Moving Average | 14.84 |
| 200-Day Moving Average | 14.23 |
| Relative Strength Index (RSI) | 38.06 |
| Average Volume (20 Days) | 3,440,370 |
Short Selling Information
| Short Interest | 4.53M |
| Short Previous Month | 6.50M |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 1.86 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $30.60 billion and earned $720.73 million in profits. Earnings per share was $0.45.
| Revenue | 30.60B |
| Gross Profit | 20.10B |
| Operating Income | 3.76B |
| Pretax Income | 366.81M |
| Net Income | 720.73M |
| EBITDA | 8.24B |
| EBIT | 3.76B |
| Earnings Per Share (EPS) | $0.45 |
Full Income StatementBalance Sheet
The company has $2.57 billion in cash and $33.98 billion in debt, giving a net cash position of -$31.41 billion or -$19.96 per share.
| Cash & Cash Equivalents | 2.57B |
| Total Debt | 33.98B |
| Net Cash | -31.41B |
| Net Cash Per Share | -$19.96 |
| Equity (Book Value) | 46.32B |
| Book Value Per Share | 29.43 |
| Working Capital | 97.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.06 billion and capital expenditures -$1.34 billion, giving a free cash flow of $5.76 billion.
| Operating Cash Flow | 7.06B |
| Capital Expenditures | -1.34B |
| Free Cash Flow | 5.76B |
| FCF Per Share | $3.66 |
Full Cash Flow StatementMargins
Gross margin is 65.70%, with operating and profit margins of 12.29% and 2.36%.
| Gross Margin | 65.70% |
| Operating Margin | 12.29% |
| Pretax Margin | 3.82% |
| Profit Margin | 2.36% |
| EBITDA Margin | 26.92% |
| EBIT Margin | 12.29% |
| FCF Margin | 18.84% |
Dividends & Yields
This stock pays an annual dividend of $0.54, which amounts to a dividend yield of 3.80%.
| Dividend Per Share | $0.54 |
| Dividend Yield | 3.80% |
| Dividend Growth (YoY) | 8.72% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 120.98% |
| Buyback Yield | -1.58% |
| Shareholder Yield | 2.21% |
| Earnings Yield | 1.60% |
| FCF Yield | 12.78% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.11 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.11 |
| Piotroski F-Score | 6 |
